NCI-H2347 Cells

The NCI-H2347 cell line is a human non-small cell lung cancer (NSCLC) cell line derived from a lung adenocarcinoma. This cell line is widely used in studies of lung cancer biology, particularly for research involving tumor suppressor gene mutations and pathways involving apoptosis, chemotherapy resistance, and viral-based cancer therapies. NCI-H2347 has wild-type p53, which contrasts with many lung cancer cell lines that harbor p53 mutations, making it a relevant model for studying the differences in therapeutic response based on p53 status. This cell line has been utilized in experiments to test the efficacy of novel treatments such as ONYX-015, a genetically modified adenovirus that selectively replicates in and lyses tumor cells with non-functional p53. While ONYX-015 was highly effective in lung cancer cell lines with p53 mutations, such as NCI-H522, its effect on NCI-H2347, which has wild-type p53, was limited. Additionally, NCI-H2347 has been involved in studies focusing on MET signaling, particularly in relation to resistance to EGFR tyrosine kinase inhibitors (TKIs). It has been shown that while MET gene amplification is not observed in this cell line, its MET protein can still be activated by EGFR mutations, suggesting a complex interplay between MET and EGFR signaling pathways.